Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
M&A / Property Routine +

TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

By The Northwire Desk — AI Analysis Jun 26, 2026 · 16:11 VIVI · 0.585 TempraMed Technologies Ltd.
Executive Summary
  • TempraMed Technologies signed a non-binding Letter of Intent (LOI) with Rawafed Health International Company to establish a 5-year exclusive distribution agreement for its temperature-sensitive medication storage products in Saudi Arabia.
  • The proposed arrangement includes minimum purchase commitments of approximately US$3.1 million over the 5-year term.
  • Exclusivity is contingent upon successful regulatory approval from the Saudi Food and Drug Authority (SFDA) and the placement of a first commercial order of at least US$170,000.
  • The partnership targets Saudi Arabia's rapidly growing diabetes and GLP-1 therapy market, leveraging Rawafed's local regulatory and commercialization capabilities to launch the VIVI Cap and future solutions.
  • The LOI is non-binding, with no guarantee of a definitive agreement or execution on contemplated terms.
Material Impact
  • The Saudi Arabia LOI represents an incremental step in TempraMed's ongoing global distribution expansion, following similar agreements in Brazil, Turkey, Benelux, Israel, and Panama over the past six months.
  • The financial commitment is modest, averaging ~$620,000 annually over five years, which is small relative to the company's current cash position and operating burn rate.
  • As a non-binding LOI contingent on regulatory approval and an initial order, it carries no immediate revenue recognition or cash flow impact.
  • The announcement does not alter the company's fundamental liquidity profile or address the going concern warning issued in the Q1 2026 financials.
VIVI · Price
Company Overview
  • TempraMed Technologies Ltd. develops and commercializes battery-free, passive thermal-insulation devices designed to protect temperature-sensitive medications (insulin, GLP-1s, biologics, epinephrine) from heat and temperature excursions.
  • The product portfolio includes VIVI Cap, VIVI Cap Smart, VIVI Epi, VIVI Med, and the upcoming VIVI Box platform.
  • The company is executing a strategic pivot from direct-to-consumer online sales to a B2B distribution model, partnering with pharmacy chains, HMOs, and regional distributors across North America, Europe, the Middle East, and Latin America.
  • The company holds multiple international patents and has secured FDA registration for its core devices, while pursuing reimbursement validation through independent ROI models.
Read the original news release →

More from TempraMed Technologies Ltd.

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 22, 2026 · 11:58

TempraMed Technologies Ltd.

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property Mar 30, 2026 · 16:52

Tempramed signs LOI for Panama distribution expansion

M&A / Property